Iterum Therapeutics plc (ITRMF) Change in Account Payables (2017 - 2025)

Iterum Therapeutics' Change in Account Payables history runs 9 years deep, the most recent figure standing at -$612000.0 for Q3 2025.

• In Q3 2025, Change in Account Payables fell 4471.43% year-over-year to -$612000.0; the TTM figure through Sep 2025 stood at -$258000.0 (up 94.49% YoY), while the FY2024 annual figure was -$4.7 million, down 313.45% from the prior year.
• Change in Account Payables for Q3 2025 stood at -$612000.0, down from $777000.0 in the prior quarter.
• The five-year high for Change in Account Payables was $1.8 million in Q3 2023, with the low at -$2.1 million in Q2 2024.
• The 5-year median for Change in Account Payables is $92000.0 (2021), against an average of -$12526.3.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables soared 1337.86% in 2023, then plunged 4471.43% in 2025.
• Iterum Therapeutics' Change in Account Payables stood at $603000.0 in 2021, then jumped by 156.05% to $1.5 million in 2022, then sank by 133.55% to -$518000.0 in 2023, then decreased by 12.74% to -$584000.0 in 2024, then declined by 4.79% to -$612000.0 in 2025.
• Business Quant data shows ITRMF's Change in Account Payables at -$612000.0 in Q3 2025, $777000.0 in Q2 2025, and $161000.0 in Q1 2025.